Abstract: Provided herein are compositions, systems, and methods comprising effector proteins, and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the epigenetic modification of nucleic acids.

Abstract: Bio-production processes that rely on biological activity can be very slow and inefficient, yet, the output of these processes may have significant value. Using biological enzymes outside their natural cellular environments offers a significant and largely untapped opportunity to enhance bio-production processes. By decoupling enzymes from their native contexts, one can modify both their sequences and structures in ways that are favorable for industrial applications. This system and method mixes substrate molecules, PPi, and enzymes that utilize PPi (PPi-dependent enzymes) in a reaction chamber and ends with stable-form products, including phosphorylated molecules.

Abstract: Disclosed herein are systems, compositions, and methods for modifying the human dystrophin gene (DMD). Systems, compositions, and methods may comprise a compact Type V CRISPR-associated (Cas) protein, an RNA-dependent DNA polymerase, and/or one or more guide nucleic acids or uses thereof. These systems, compositions, and methods may be useful for treating diseases such as Duchenne muscular dystrophy (DMD).

Abstract: Provided herein are compositions, systems, and methods for modifying a human APOC3 gene, PCSK9 gene, or ANGPTL3 gene. Systems, compositions, and methods may comprise a CRISPR-associated (Cas) protein or uses thereof. Systems, compositions, and methods of the present disclosure may be useful for treatment of APOC3 associated conditions, including familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG).

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins for treating DUX4 mutations. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering the DUX4 gene.

Abstract: Disclosed herein are composition and methods of modifying a target double-stranded DNA (dsDNA) molecule in a cell. Systems, compositions, and methods may comprise a CRISPR-associated (Cas) protein, an RNA-dependent DNA polymerase, and/or one or more guide nucleic acids or uses thereof.

Abstract: Provided herein are compositions, systems and methods for allele-specific editing of a target gene in a cell, comprising contacting the cell with an effector protein or a polynucleotide encoding the same, and a guide nucleic acid or a polynucleotide encoding the same. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering the NRAS or KRAS gene.

Abstract: Provided herein are compositions, systems, and methods comprising engineered effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Provided herein are compositions, systems, and methods for engineering hematopoietic stem cells that engineered by using polypeptides, such as effector proteins, and guide nucleic acids. Also, provided herein are the engineered hematopoietic stem cells, methods of manufacturing such hematopoietic stem cells, and methods of treating a disease or disorder using such hematopoietic stem cells.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: The present disclosure describes the engineering of microbial cells for fermentative production of ectoine and provides novel engineered microbial cells and cultures, as well as related ectoine production methods.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

Abstract: Systems, methods, and non-transitory computer-readable media are described for identifying candidate biological sequences for screening to determine whether the candidate biological sequences enable a biological function. Identification may be based upon (a) degrees of similarity between test sequences and reference sequences that are known to enable the function, and (b) comparisons of regions in the test sequences to reference regions that are known to bind to a molecule. Identification may also be based upon determining sequence similarities between reference sequences, grouping the reference sequences into clusters that each correspond to a molecule that is indicated as capable of being bound by a reference sequence in the cluster, and identifying matching test sequences based upon a comparison of the test sequences with reference sequences in the clusters.

Abstract: The present disclosure describes the engineering of microbial cells for fermentative production of 2-oxoadipate and provides novel engineered microbial cells and cultures, as well as related 2-oxoadipate production methods.